Mourabit Halima, Author at MediaMedic

2024 CUDA丨Dr. Guohua Zeng: China’s Leading Role in Minimally Invasive Urological Stone Surgery, Enhancing Patient Quality of Life

By Mourabit Halima 2024.08.31

The 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi'an from August 8 to 11, 2024. The conference, organized by the Chinese Medical Association and the CUDA Urological Surgeons Branch, was hosted by the Air Force Medical University Xijing Hospital and co-organized by the Shaanxi Provincial Medical Association Urological Surgeons Branch. The event showcased the latest achievements in urology from a broad and diverse perspective. During the conference, Urology Frontier interviewed the Honorary Chairman of the conference, Dr. Guohua Zeng from The First Affiliated Hospital of Guangzhou Medical University, who shared insights on the remarkable achievements of minimally invasive urological stone surgery in China, the development trends of percutaneous nephrolithotomy (PCNL), and valuable suggestions for improving the treatment and quality of life for patients with urinary stones.

Dr. Hailiang Zhang: Analyzing the Characteristics of Chinese UTUC Patients and Exploring Targeted Treatment Strategies to Meet the Needs of More UTUC

By Mourabit Halima 2024.08.31

Upper tract urothelial carcinoma (UTUC), which includes renal pelvis cancer and ureteral cancer, is classified alongside bladder cancer as a type of urothelial carcinoma. However, the overall incidence of UTUC is relatively low, and there are still some contentious issues in its diagnosis and treatment strategies. At the recent 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association held in Xi'an, Dr. Hailiang Zhang from Fudan University Shanghai Cancer Center delivered an insightful lecture titled "Systemic Treatment of UTUC: Challenges, Breakthroughs, and Future Directions." Following the conference, Urology Frontier invited Professor Zhang to discuss the characteristics of UTUC patients in China, perioperative treatment strategies, and the progress of his research team.

2024 CUDA丨Dr. Tie Zhong: New Endocrine Therapies Improve Prognosis in mHSPC, Optimizing Precision Treatment Through Stratified Approaches

By Mourabit Halima 2024.08.31

The 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi'an from August 8 to 11, 2024. The conference was hosted by the Chinese Medical Association and the CUDA Urological Surgeons Branch, with the Air Force Medical University Xijing Hospital serving as the organizer and the Shaanxi Provincial Medical Association Urological Surgeons Branch as a co-organizer. Under the theme "Healthy China, Urology First," the conference showcased the latest achievements in urology. At the event, Urology Frontier interviewed Dr. Tie Zhong from The Second Affiliated Hospital of Xi'an Jiaotong University to review the recent progress in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China. The discussion focused on the benefits of new endocrine therapies and individualized treatment strategies, providing guidance for the future development of mHSPC.

2024 CUDA丨Dr. Jian Huang: Exploring the Potential Benefits of Robot-Assisted Function-Preserving Radical Cystectomy for Bladder Cancer Patients

By Mourabit Halima 2024.08.30

Robot-assisted radical cystectomy is playing an increasingly significant role in the treatment of bladder cancer. At the 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) held in Xi'an from August 8 to 11, Dr. Jian Huang from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, shared his insights on "Robot-Assisted Function-Preserving Radical Cystectomy." After the conference, Urology Frontier invited Professor Huang to delve deeper into this topic.

2024 CUDA丨Dr. Wei Yu: Optimal ADC Strategies in the Systemic Treatment of Urothelial Carcinoma

By Mourabit Halima 2024.08.30

Urothelial carcinoma (UC) is one of the most common malignancies in the urinary system. With the increasing availability of ADC (antibody-drug conjugate) drugs in clinical practice, optimizing ADC drug selection and combination therapies, as well as managing treatment-related adverse events, have become critical issues. Following the successful 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) in Xi'an, Urology Frontier invited Dr. Wei Yu from Peking University First Hospital to share insights on optimal ADC strategies for the systemic treatment of UC.

2024 CUDA丨Dr. Xiangjun Lyu: Addressing Incontinence Early, Enhancing Pelvic Floor Disease Outcomes with Robotic Surgery

By Mourabit Halima 2024.08.30

The 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi'an from August 8 to 11, 2024. The conference was hosted by the Chinese Medical Association and the CUDA Urological Surgeons Branch, with the Air Force Medical University Xijing Hospital serving as the organizer and the Shaanxi Provincial Medical Association Urological Surgeons Branch as a co-organizer. Under the theme "Healthy China, Urology First," the conference showcased the latest achievements in urology. At the event, Dr. Xiangjun Lyu from the Chinese PLA General Hospital spoke with Urology Frontier about the importance of correcting patient perceptions regarding urinary incontinence and pelvic floor diseases, emphasizing the benefits of early diagnosis and intervention. She also discussed the role of robotic surgery in improving treatment outcomes for these conditions and its future prospects.

The First Mid-Term Milestone of the End TB Strategy: Global Progress and Key Findings

By Mourabit Halima 2024.08.30

Editor's Note: Tuberculosis (TB) remains a significant public health challenge worldwide, particularly in economically underdeveloped regions. Although progress has been made in TB diagnosis and treatment in recent years, factors…

Are OTC Eye Drops Safe? CRPA Outbreaks in Multiple U.S. States Trace Back to Artificial Tears

By Mourabit Halima 2024.08.30

Editor's Note: Artificial tears are substitutes that mimic the composition of natural tears, providing lubrication to the eyes and alleviating symptoms of dry eye, such as pain and burning. However,…

Cutting-edge Bi-monthly: July Literature Digest (Part 1)

By Mourabit Halima 2024.08.29

In this era of information explosion, how can one quickly access the latest developments in the field? Here, we select the latest literature in the field every month, focusing on hot topics, comprehensively interpreting new advances in hematologic diseases, and helping you stay at the forefront of the disease field. Let's track the latest trends together, gain insights into research trends, and explore the boundless possibilities in the world of hematology! Stay tuned every month for the latest updates!

Conference Preview: The 11th Sino-French Hematology Summit of the Chinese Medical Doctor Association will be held in Tianjin in mid-September

By Mourabit Halima 2024.08.29

The "11th Sino-French Hematology Summit of the Chinese Medical Doctor Association," organized by the Chinese Medical Doctor Association, the Hematology Branch of the Chinese Medical Doctor Association, and the French Hematology Association, and hosted by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) and the National Clinical Research Center for Hematological Diseases—Peking University Hematology Institute, with the support of the French Bo Xiao Foundation under the French Fund General Assembly, is scheduled to be held in Tianjin from September 13 to 15, 2024. The conference theme focuses on "New Advances in the Treatment of Hematological Malignancies," delving into the latest clinical diagnosis and treatment progress, current hot topics, and core challenges in clinical practice related to the hematopoietic system. This conference sincerely invites authoritative experts in the field of hematology from both international and domestic circles to share their insights and experiences. It is planned to invite 150 hematologists from across the country to participate and exchange academic experiences. We warmly welcome clinicians on the front line of hematology to actively participate in the meeting and jointly promote progress in the field of hematological malignancy treatment.